Tislelizumab and Zeprumetostat for Lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have NK/T-cell lymphoma that came back or did not get better after at least one prior chemotherapy treatment.
- You must be well enough to be up and about for at least half the day (ECOG score 0 to 2).
- You cannot have taken an EZH1/2 or EZH2 inhibitor before.
- You must not have active infections like tuberculosis, HIV, or uncontrolled hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new drug called zeprumetostat (an EZH2 inhibitor) combined with other treatments for people with mature T-cell or NK-cell lymphoma that has come back or not responded to standard therapy. The goal is to see if the combination can help control the lymphoma.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.